trial

Phosphatidylcholine Supplementation in Infants

NCTId NCT01905605
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by University of Colorado, Denver
Primary completion 2017-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-09
Primary completion
2017-01
Eligibility
ALL · 1 Week · 7 Weeks

Interventions & indications

Drugs
phosphatidylcholine supplementation

Sponsors

University of Colorado, DenverLead Sponsor

Investigators

1
Robert Freedman, MDPrincipal Investigator

Sites

1 total
Aurora, United States

Linked catalysts

1
Phosphatidylcholine Supplementation in Infants — primary completion2017-01

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE1,PHASE2
Primary Completion Date
2017-01
Status
WITHDRAWN
relationships
The graph out of here
drug
phosphatidylcholine supplementation
drug
lead_sponsor
University of Colorado, Denver
company
indication
Schizophrenia
indication
Schizophrenia
indication
Diminished P50 Sensory Gating
indication
investigator
Robert Freedman, MD
person